To next test the hypothesis that, in addition to the overall abundance of pTRC, the MANAscore itself could be used to categorize responding vs non-responding tumors after anti-PD-1 therapy, we computed the average overall MANAscore for each tumor sample and found a higher, albeit not statistically significant, average MANAscore in MPR than non-MPR tumors (p = 0.088; Fig. 6C). The gene discussed is PDCD1; the disease is neoplasm.